Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Uveal melanoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Uveal melanoma. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-003164-50 Sponsor Protocol Number: CEUSUM Start Date*: 2012-10-19
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: CONTRAST ENHANCED ULTRASOUND (CEUS) IN UVEAL MELANOMA: QUANTITATIVE ASSESSMENT OF TUMOR RESPONSE TO GAMMA KNIFE RADIOSURGERY (GKR)
    Medical condition: patients affected by uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061252 Intraocular melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024415-14 Sponsor Protocol Number: 184151 Start Date*: 2011-05-12
    Sponsor Name:Institut Català d’Oncologia (ICO)
    Full Title: Ensayo clínico fase II, no randomizado, para evaluar el papel de Ipilimumab en monoterapia, administrado en primera línea en pacientes afectos de melanoma uveal metastásico. "Phase II multi-center...
    Medical condition: MELANOMA UVEAL METASTASICO
    Disease: Version SOC Term Classification Code Term Level
    13 10025650 Melanoma maligno LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000564-29 Sponsor Protocol Number: SUGBG-013001 Start Date*: 2013-04-25
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
    Medical condition: Uveal melanoma liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007847-28 Sponsor Protocol Number: DERMA-ER-DC08 Start Date*: 2011-09-16
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected m...
    Medical condition: Patients with resected uveal melanoma showing monosomy 3, free of metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003380-95 Sponsor Protocol Number: CDYP688A12101 Start Date*: 2022-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
    Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) NO (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001974-33 Sponsor Protocol Number: 08/014 Start Date*: 2009-04-14
    Sponsor Name:Radboud University Nijmegen Medical Centre [...]
    1. Radboud University Nijmegen Medical Centre
    2. Rotterdam Eye Hospital
    Full Title: mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients
    Medical condition: Our study population consists of HLA-A2.1 positive patients with a high risk uveal melanoma (stage II) with proven expression of melanoma associated antigens tyrosinase and/or gp100. Patients are i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004429-15 Sponsor Protocol Number: GEM-1402 Start Date*: 2016-02-16
    Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA
    Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma.
    Medical condition: Metastatic uveal melanoma non suitable for radical resection.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022687-12 Sponsor Protocol Number: STREAM Start Date*: 2011-03-17
    Sponsor Name:Universitätsklinikum Essen
    Full Title: A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma (Sorafenib Treatment of Metastatic Uveal Melanoma)
    Medical condition: choroid melanoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008773 Choroid melanoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003188-24 Sponsor Protocol Number: CA184-587 Start Date*: 2020-11-13
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004200-38 Sponsor Protocol Number: N11RFA Start Date*: 2012-03-28
    Sponsor Name:NKI-AVL
    Full Title: Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM)
    Medical condition: Unresectable uveal melanoma liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002245-12 Sponsor Protocol Number: EORTC 18021 Start Date*: 2005-01-27
    Sponsor Name:European Organisation for the Research and Treatment of Cancer
    Full Title: Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.
    Medical condition: Uveal melanomas with specific hepatic tropism
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002439-32 Sponsor Protocol Number: SirTac2014 Start Date*: 2015-10-22
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from U...
    Medical condition: Liver Metastases from Uveal Melanoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000281-11 Sponsor Protocol Number: CMEK162X2203 Start Date*: 2013-07-15
    Sponsor Name:Novartis Pharma Services
    Full Title: A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma
    Medical condition: Uveal Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) GB (Prematurely Ended) IT (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2021-002474-99 Sponsor Protocol Number: GEM-2101 Start Date*: 2022-09-07
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma (GEM)
    Full Title: Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.
    Medical condition: Metastatic Uveal Melanoma with liver metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001925-15 Sponsor Protocol Number: ISS20159321 Start Date*: 2018-10-22
    Sponsor Name:Alcedis GmbH
    Full Title: Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant me...
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002037-42 Sponsor Protocol Number: SGNS40-002 Start Date*: 2022-03-17
    Sponsor Name:Seagen Inc.
    Full Title: An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
    Medical condition: Melanoma; Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003545-41 Sponsor Protocol Number: D1344C00001 Start Date*: 2014-04-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic...
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) NL (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008794-55 Sponsor Protocol Number: RDD299 Start Date*: 2010-05-17
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma
    Medical condition: Metastatic Uveal Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005737-11 Sponsor Protocol Number: PH-L19IL2 DTIC - 03/07 Start Date*: 2008-01-17
    Sponsor Name:PHILOGEN S.P.A.
    Full Title: Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma
    Medical condition: unresectable metastatic (stage IV)non-uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025654 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000961-10 Sponsor Protocol Number: NITRO Protocol Start Date*: 2011-12-07
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals Trust
    Full Title: Neoadjuvant IntraviTreal Ranibizumab treatment in high risk Ocular melanoma patients: A two stage single centre Phase II single arm study (NITRO Trial)
    Medical condition: Uveal Melanoma (requiring enucleation)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 00:33:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA